These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 15170969)

  • 21. [Analysis of generic drug supply in France].
    Taboulet F; Haramburu F; Latry P
    Rev Epidemiol Sante Publique; 2003 Sep; 51(4):415-25. PubMed ID: 13679734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Generic drug substitution].
    Tamir O; Halkin H; Shemer J
    Harefuah; 2006 Sep; 145(9):691-5, 701. PubMed ID: 17078434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generic medicine pricing in Europe: current issues and future perspective.
    Simoens S
    J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic aspects of the new Spanish laws on pharmaceutical preparations.
    Antoñanzas F; Oliva J; Pinillos M; Juàrez C
    Eur J Health Econ; 2007 Sep; 8(3):297-300. PubMed ID: 17401592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.
    Fraeyman J; Verbelen M; Hens N; Van Hal G; De Loof H; Beutels P
    Appl Health Econ Health Policy; 2013 Oct; 11(5):543-52. PubMed ID: 24062144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmaceutical policy in Italy: towards a structural change?
    Ghislandi S; Krulichova I; Garattini L
    Health Policy; 2005 Apr; 72(1):53-63. PubMed ID: 15760698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Generics market in Greece: the pharmaceutical industry's beliefs.
    Geitona M; Zavras D; Hatzikou M; Kyriopoulos J
    Health Policy; 2006 Nov; 79(1):35-48. PubMed ID: 16386326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
    Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
    Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of generic reference pricing interventions in the statin market.
    Puig-Junoy J
    Health Policy; 2007 Nov; 84(1):14-29. PubMed ID: 17368619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pricing and reimbursement of pharmaceuticals in Sweden.
    Jönsson B
    Pharmacoeconomics; 1994; 6 Suppl 1():51-60. PubMed ID: 10172482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis.
    Garattini L; Cornago D; De Compadri P
    Health Policy; 2007 Aug; 82(3):330-9. PubMed ID: 17125881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals.
    Andersson K; Bergström G; Petzold MG; Carlsten A
    Health Policy; 2007 May; 81(2-3):376-84. PubMed ID: 16945449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Price control as a strategy for pharmaceutical cost containment - what has been achieved in Norway in the period 1994-2004?
    Håkonsen H; Horn AM; Toverud EL
    Health Policy; 2009 May; 90(2-3):277-85. PubMed ID: 19042052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Out-of-pocket and total costs of fixed-dose combination antihypertensives and their components.
    Rabbani A; Alexander GC
    Am J Hypertens; 2008 May; 21(5):509-13. PubMed ID: 18437141
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmaceutical pricing and reimbursement reforms in Greece.
    Yfantopoulos J
    Eur J Health Econ; 2008 Feb; 9(1):87-97. PubMed ID: 17619920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Medical problems and risks of switching drugs according to legal requirements of drug discount contracts in Germany].
    Pruszydlo MG; Quinzler R; Kaltschmidt J; Haefeli WE
    Dtsch Med Wochenschr; 2008 Jul; 133(27):1423-8. PubMed ID: 18592450
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hospital reimbursement price cap for cancer drugs: the French experience in controlling hospital drug expenditures.
    Degrassat-Théas A; Bensadon M; Rieu C; Angalakuditi M; Le Pen C; Paubel P
    Pharmacoeconomics; 2012 Jul; 30(7):565-73. PubMed ID: 22686661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Assessment of annual health insurance reimbursement for oncology drugs in Hungary].
    Boncz I; Donkáné Verebes E; Oberfrank F; Kásler M
    Magy Onkol; 2010 Dec; 54(4):283-8. PubMed ID: 21163758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.